Board Member
Artiva Biotherapeutics, Inc. (ARTV)Equibles does not estimate personal net worth.
Get an email with a short summary when Artiva Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ARTV alertsFred Aslan is recorded as Board Member and CEO at Artiva Biotherapeutics, Inc. (ARTV). The newest filing on record that lists Fred Aslan as Board Member and CEO at Artiva Biotherapeutics, Inc. (ARTV) is dated August 3, 2026. The proxy statement of Artiva Biotherapeutics, Inc. reports total compensation of $6,671,215 for Fred Aslan in fiscal 2025, including a base salary of $665,000. Disclosed compensation is on record for 2 fiscal years. Fred Aslan has spoken on 4 investor events across 1 company, most recently for Artiva Biotherapeutics, Inc. on September 14, 2026. Artiva Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Artiva Biotherapeutics, Inc. includes Fred Aslan, M.D. (CFO), Neha Krishnamohan (CFO), Thad Huston (CFO) and 7 others.
“So Arteva is a phase three company pursuing refractory RA. As you mentioned, we are one of the companies that's pursuing the very exciting mechanism of deep B-cell depletion.”
“So we have demonstrated across a variety of trials in both oncology and autoimmune disease that Allo-NK is a very potent, deep B-cell depleting product. Specifically, where we have generated the most data to date in autoimmune disease has been in refractory RA.”
“I would argue that the data that has been presented by Autocar T in autoimmunity is probably the most potent mechanism that we are seeing today in terms of the possibility of taking refractory patients and giving them durable responses.”
“So Artiva was founded in 2019 on the back of technology to massively scale NK cells that has been developed for a decade prior from a Korean company called GC Cell.”
Start not stated–present
Last confirmed August 3, 2026
Start not stated–present
Last confirmed August 3, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Artiva Biotherapeutics, Inc. (ARTV) | Chief Executive Officer | $665,000 | $6,671,215 |
| 2024 | Artiva Biotherapeutics, Inc. (ARTV) | Chief Executive Officer | $621,583 | $7,827,788 |
